Pricing Log in Create free account
Saturday 7 November 2026 Export VALN’s income statement to Excel — free account

Valneva SE Sponsored ADR

VALN Healthcare Biotechnology

Valneva SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $197.6 million, up 7.69% from fiscal 2024.

Revenue
−17.3%
EPS
−222.1%
Free cash flow
−56.1%
Total debt
+12.1%

Quarter to June 2026, against a year earlier

5.57 0.07 −1.24%
Market cap
$536.5M
P/E
59.3×
Fwd P/E
19.4×
Dividend yield
—
F-score
2/9
Altman Z
−0.49
Beneish M
−3.28
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 536.53
Revenue ttm 164.10
Net income ttm (163.66)
Free cash flow ttm (58.90)
Net debt Q 72.71
Valuation
P/E 59.26 (above 35: high)
Forward P/E 19.40
Price / sales 3.02
Forward P/S Powerpack
Price / FCF 0.00
Price / book 5.26
Financial health
Current ratio Q 2.16 (at or above 1.5: strong)
Debt / equity Q 2.27 (above 2: weak)
Interest coverage Q (4.65)
Growth
Revenue growth Q −17.29% (below 0%: shrinking)
Operating income growth Q −34.15% (below 0%: shrinking)
EPS, this year +34.96% (at or above 15%: strong)
EPS, next year A +161.52% (at or above 15%: strong)
Revenue, next year A +1,162.90% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +58.87% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.5×, against a ten-year median of 3.4×; over the ten years it ranged from 1.3× in 2023 to 19.9× in 2021.
P/S against its own 10 years 39.42%
10-year low 10-year high
P/B against its own 10 years 66.14%
10-year low 10-year high
EV/Sales against its own 10 years 48.88%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 136 182 124 141
Receivables 45 38 31 19
Inventory 48 58 57 56
Other 55 45 39 41
284 324 252 259
2023 2024 2025 Q'26
Payables 48 38 28 27
ST’ Debt 48 23 20 21
Other 55 37 32 44
172 124 106 120

Compound Annual Growth %

10y 5y 3y
Sales — 9.41% (19.63%)
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 6.31% (19.65%)

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate −0.28 Actual −0.40

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 −0.30 −0.61 Miss by 0.31
Dec 2025 −0.21 −0.68 Miss by 0.47
Mar 2026 −0.21 −0.42 Miss by 0.21
Jun 2026 −0.28 −0.40 Miss by 0.12
Sep 2026 −0.23 — Reports 19 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.42) — — — —
’25 (0.13) — — — (1.54)
’24 0.89 — — — (0.17)
’23 (0.28) (0.13) (0.27) — (1.57)
’22 (0.54) (1.40) 0.60 (0.34) (2.61)
’21 (0.72) (1.47) (3.77) — (1.77)
’20 (0.01) (0.30) (0.47) (0.02) (1.62)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 36 — — — —
’25 52 — — — 198
’24 36 — — — 184
’23 36 44 41 — 166
’22 25 74 152 119 381
’21 28 29 26 — 412
’20 39 14 13 64 126
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 (16) — — —
’25 (9) (4) (33) — (60)
’24 (31) (40) (84) — (73)
’23 (26) (47) (149) — (219)
’22 (30) (79) (89) (62) (258)
’21 57 43 (59) — 91
’20 3 122 (44) 157 157
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (16) — — —
’25 (10) (5) (37) — (65)
’24 63 (139) (106) — (90)
’23 (30) (51) (154) — (235)
’22 (41) (85) (112) (62) (289)
’21 37 16 (59) — (19)
’20 3 122 (44) 136 135
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 99 127 130 142 126 412 381 166 184 198 164 +8.0% — — — —
Gross margin, % 44.92 48.19 57.87 56.87 50.78 46.01 10.20 34.37 41.89 38.66 38.28 (6.3) pt
EBT (51) (15) 3 (10) (75) (83) (153) (107) (12) (129) (14) +10.8%
EBT margin, % (51.91) (11.93) 1.97 (6.94) (59.19) (20.10) (40.08) (64.16) (6.77) (65.34) (8.74) (13.4) pt
Net income (52) 0 4 (2) (74) (87) (151) (110) (13) (130) (164) +10.8%
Per share, $
Per share, $ Revenue 2.44 2.31 3.23 3.09 2.78 8.44 6.59 2.40 2.52 2.35 1.84 (0.4%)
Earnings (1.28) (0.25) 0.05 (0.02) (1.62) (1.77) (2.61) (1.57) (0.17) (1.54) 0.09 +2.1%
Cash flow (0.03) 0.17 0.35 0.08 3.47 1.86 (4.48) (3.17) (1.00) (0.71) 0.00 +42.4%
Capex 0.00 0.00 0.00 0.00 (0.49) (2.26) (0.53) (0.22) (0.24) (0.06) 0.00 n/m
Free cash flow (0.03) 0.17 0.35 0.08 2.98 (0.39) (5.01) (3.39) (1.24) (0.77) 0.00 +43.7%
Book value 2.59 2.03 4.09 3.31 1.95 4.13 4.01 2.00 2.69 1.43 0.00 (6.4%)
Shares, m 41 55 40 46 45 49 58 69 73 84 76 +8.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18.71 22.99 59.26 4.2
P/S 10.28 10.28 10.28 10.28 10.28 18.65 2.55 2.98 1.97 3.95 3.02 8.1
P/B 19.32 19.32 19.32 19.32 19.32 29.76 4.03 4.14 1.28 3.86 5.26 14.0
EV/Sales 8.44 8.44 8.44 8.44 8.44 16.87 2.16 2.84 2.08 4.12 3.47 7.0
EV/FCF 3.41 3.41 3.41 3.41 3.41 12.42 (2.43) (2.12) (0.96) (4.45) (9.66) 2.0
Cash, $m
Cash, $m Operating cash flow (1) 10 14 3 157 91 (258) (219) (73) (60) (53) +54.4%
Capex (4) (5) (4) (12) (22) (110) (31) (15) (18) (5) (6) +2.7%
Free cash flow (1) 10 14 3 135 (19) (289) (235) (90) (65) (59) +55.8%
Balance, $m
Balance, $m Working capital 55 55 95 99 151 257 155 113 200 146 139 +11.5%
Net debt 42 40 (28) 23 (173) (342) (201) 55 21 79 73 +7.1%
Shareholders’ equity 105 112 165 152 88 202 232 139 196 120 94 +1.5%
Returns, %
Returns, % ROA (23.22) (12.70) 1.52 (0.67) (17.92) (11.74) (18.62) (19.05) (2.55) (26.27) 0.00 (3.0) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 (243.03) (28.66) 4.16 (29.19) 0.00 (29.2) pt
ROE (47.72) (12.75) 2.72 (1.24) (61.22) (59.86) (69.66) (59.28) (7.91) (82.42) 0.00 (34.7) pt
People
People Employees — — — — 640 762 719 676 713 674 — +1.0%
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.20 0.54 0.53 0.25 0.26 0.29 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Valneva SE Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ACRS Aclaris Therapeutics, Inc. $559.5M — (loss-making) — (loss-making) −55.11% (below 0%: shrinking) n/m −119.93% (below 0%: shrinking) 0.00% (1,441.19%) Compare
IAM Iambic Therapeutics, Inc. $551.7M — — — — — — — Compare
BCAX Bicara Therapeutics Inc. $542.0M — (loss-making) — — n/m −72.95% (below 0%: shrinking) — 0.00% Compare
VALN Valneva SE Sponsored ADR $536.5M 59.3× 19.4× −17.29% (below 0%: shrinking) n/m −56.05% (below 0%: shrinking) 15.29% (76.67%)
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR $524.8M — (loss-making) — (loss-making) −7.53% (below 0%: shrinking) n/m −31.52% (below 0%: shrinking) 0.00% 0.00% Compare
ENTX Entera Bio Ltd. $520.0M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m −108.86% (below 0%: shrinking) 0.00% 0.00% Compare
FTH Faeth Therapeutics, Inc. $514.8M — (loss-making) — — n/m −262.66% (below 0%: shrinking) 0.00% 0.00% Compare
NGNE Neurogene Inc. $513.3M — (loss-making) — (loss-making) — n/m −22.97% (below 0%: shrinking) 100.00% 0.00% Compare
CLYM Climb Bio, Inc. $509.5M — (loss-making) — — n/m +3.73% (above 0%: growing) — 0.00% Compare
Median of peers $522.4M — — −7.53% — −72.95% 0.00% 0.00%

All 621 Biotechnology stocks →

Valneva SE Sponsored ADR (VALN) Latest News

21 Oct

Impact 3 · · pharmaceutical-technology.com

14 Oct

Impact 4 · · GlobeNewswire

7 Oct

Impact 4 · · Stocktwits
Impact 3 · · Investing.com
Impact 3 · · GlobeNewswire

15 Sep

Impact 4 ·

28 Aug

Impact 3 ·

20 Aug

Impact 4 · · The Motley Fool transcript

18 Aug

Impact 4 ·

14 Aug

Impact 4 · · Stocktwits
Impact 4 ·
Impact 4 ·

13 Aug

Impact 4 ·
Impact 4 ·
Impact 3 · · MarketBeat transcript

13 May

Impact 4 · · GuruFocus.com
Impact 4 · · Benzinga transcript
Impact 3 · · MarketBeat
Impact 3 · · GlobeNewswire

30 Apr

Impact 4 · · GlobeNewswire

7 Apr

Impact 4 · · Insider Monkey

1 Apr

Impact 4 · · pharmavoice.com

27 Mar

Impact 4 · · Simply Wall St.

26 Mar

Impact 3 · · Insider Monkey

24 Mar

Impact 4 · · Zacks

23 Mar

Impact 4 · · Simply Wall St.
Impact 4 · · clinicaltrialsarena.com
Impact 4 · · The Wall Street Journal
Impact 4 · · The Wall Street Journal
Impact 4 · · AFP
stockrow.com/VALN · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com